Major Depressive Disorder Study 1
Enrolling Now

Clinics: Greater Manchester and Merseyside

Therapy Area: Depression

Gender and Age: Males & Females aged 18 and over

Reimbursement: Up to £725

About The Research...

MAC Clinical Research is currently conducting a clinical trial to test an investigational drug for depression. Despite the availability of numerous methods of medical and psychological treatments, fewer than 50% of all patients with depression show full recovery with optimised treatment.

This trial will test the effect of pimavanserin (the investigational study drug) compared to placebo (inactive pill) on symptoms of depression in patients who are taking an antidepressant that hasn’t fully helped. The study drug or placebo is taken along with the current antidepressant and is taken orally as two tablets once a day.

There will be 8 visits to one of our clinics and 1 phone call from a study physician over a period of 13 weeks. There is no certainty that you will receive any medical benefit from a study physician over a period of 13 weeks. There is no certainty that you will receive any medical benefit from taking part in this study.

Criteria:

Key Inclusion Criteria*

  • Male or female aged 18+
  • Diagnosis of depression
  • Currently taking a stable dosage of eligible SSRI/SNRI

 

Key Exclusion Criteria*

  • Unstable health condition
  • History of epilepsy

Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.

Key Inclusion Criteria

  •  

Key Exclusion Criteria

  •  

MAC Clinical Research is conducting a trial to evaluate a potential new treatment for depression

If you would like more information, please fill in the form below and we will be in touch…

Alternatively, please call our recruitment team on freephone 0800 633 5507.

  • (You can enter any supporting information here)
Data Privacy Statement

Know someone who may be interested in taking part? Share this page here:

Share on facebook
Facebook
Share on twitter
Twitter
Share on whatsapp
WhatsApp
Share on email
Email